Business Update Positive

2026-08-24 19:57

- Fortis Healthcare Limited received a 'Strong' ESG Rating for FY 2025-26 from Crisil ESG Ratings & Analytics Ltd. - Rating assigned: 'Crisil ESG 66' and 'Crisil Core ESG 72'.

Business Update Positive

2026-08-11 21:14

- Fortis Healthcare discussed its Q1 FY27 performance, reporting a 17.5% YoY growth in consolidated revenue to INR 2,545 crores and a 15.8% YoY growth in consolidated operating EBITDA to INR 568 crores. - The company reiterated its target of achieving a 25% consolidated EBITDA margin by FY28, including the impact of ESOP costs. - It plans to operationalize an additional 400 beds in FY27, including 200 beds at FMRI, following the addition of 100 beds in Q1. - Strategic expansion includes an O&M agreement for a 300-bedded hospital in Cuttack, entering the Odisha market, and investing INR 252 Cr for a proton therapy facility at its Gurgaon flagship hospital. - The Diagnostic business is targeting 12-13% revenue growth and 24-25% EBITDA margins, driven by B2C and specialized portfolios. - While oncology growth was impacted by chemo drug pricing, the company plans to focus on radiation and surgical oncology to achieve 10-12% growth. - Management indicated active pursuit of inorganic growth opportunities within focus clusters.

Governance Positive

2026-08-11 21:00

- Fortis Healthcare Limited held its 30th Annual General Meeting (AGM) on August 11, 2026. - All 8 resolutions proposed at the AGM were approved with the requisite majority. - Key approvals include the adoption of FY26 financial statements and a final dividend of ₹1/- per equity share. - The re-appointment of directors and the Managing Director & CEO were also approved.

Business Update Neutral

2026-08-07 14:57

- Audio recording of the Investors / Analysts meet held on Friday, August 07, 2026, to discuss the Q1 FY27 financial results is now available on the company's website.

Financials Positive

2026-08-06 19:56

- Consolidated Revenue ₹2,545 Cr vs ₹2,167 Cr (▲17.5% YoY) - EBITDA ₹568 Cr vs ₹491 Cr (▲15.8% YoY) - PAT ₹263 Cr vs ₹254 Cr (▲3.6% YoY) - EBITDA Margin 22.3% vs 22.6% (▼30bps)

Financials Positive

2026-08-06 19:41

- Consolidated Revenue ₹2,545Cr vs ₹2,167Cr (▲17.5% YoY) - EBITDA ₹568Cr vs ₹491Cr (▲15.8% YoY) - PAT ₹273Cr vs ₹267Cr (▲2.3% YoY) - EBITDA Margin 22.3% vs 22.6% (▼30bps)

Financials Negative

2026-08-06 19:34

CRITICAL RED FLAG DETECTED

- Standalone Revenue ₹489.45Cr vs ₹433.03Cr (▲13.0% YoY) - Standalone EBITDA ₹122.85Cr vs ₹128.12Cr (▼4.1% YoY) - Standalone PAT ₹47.78Cr vs ₹51.88Cr (▼7.9% YoY) - Standalone EBITDA Margin 25.10% vs 29.59% (▼449bps) - The company disclosed ongoing investigations by the SFIO and a Supreme Court directive for a forensic audit concerning transactions with RHT Health Trust and related parties.

Financials Negative

2026-08-06 19:10

CRITICAL RED FLAG DETECTED

- Standalone Revenue ₹489.45 Cr vs ₹433.03 Cr (▲13.02% YoY) - Standalone EBITDA ₹122.85 Cr vs ₹128.12 Cr (▼4.11% YoY) - Standalone PAT ₹47.78 Cr vs ₹51.88 Cr (▼7.90% YoY) - Standalone EBITDA Margin 25.10% vs 29.59% (▼449bps) - The Board approved the unaudited Standalone Financial Results for the quarter ended June 30, 2026. - M/s. BSR & Co. LLP was re-appointed as Tax Auditors for FY 2025-26. - The company is subject to ongoing investigations by various regulatory authorities (SFIO, EOW, SEBI, Supreme Court) regarding alleged improper past transactions, fund diversion, and wrongful remuneration, with several matters sub-judice and appeals pending.

Business Update Neutral

2026-08-05 17:28

- Fortis Healthcare's material subsidiary, Agilus Diagnostics Limited, approved an intra-group restructuring. - Wholly-owned subsidiaries Agilus Pathlabs Private Limited and DDRC Agilus Pathlabs Limited will merge into Agilus Diagnostics Limited via a Scheme of Arrangement. - No consideration will be payable; subject to regulatory approvals.

Business Update Neutral

2026-07-31 16:11

- Concall Schedule - Concall Date: August 07, 2026 - Concall Time: 11.00 am (IST)

Business Update Neutral

2026-07-30 18:21

- Concall Schedule - Concall Date: August 07, 2026 - Concall Time: 11.00 am (IST)

Financials Positive

2026-07-21 21:22

- Fortis Healthcare Limited's Board recommended a final dividend of Rs. 1 per equity share (face value Rs. 10) for the financial year ended March 31, 2026, at its meeting on May 22, 2026. - The dividend is subject to shareholder approval at the 30th Annual General Meeting (AGM) scheduled for August 11, 2026. - The record date for determining shareholder entitlement for the dividend is Friday, July 24, 2026. - The company has provided detailed intimation regarding Tax Deduction at Source (TDS) on the dividend, including procedures for resident and non-resident shareholders to submit declarations for exemption or lower tax deduction by August 5, 2026.

Governance Negative

2026-07-20 15:19

CRITICAL RED FLAG DETECTED

- Fortis Healthcare announced the appointment of Mr. Vijender Singh as Managing Director & Chief Executive Officer of its subsidiary, Agilus Diagnostics Limited, effective July 20, 2026. - This follows the resignation of Dr. Anand K from the MD & CEO role. - Mr. Singh brings over three decades of experience across diagnostics, healthcare, and FMCG sectors.

Financials Positive

2026-07-17 18:38

- Fortis Healthcare Limited has fixed July 24, 2026, as the record date for the payment of the final dividend of ₹1/- per equity share (10% of face value) for the financial year 2025-26. - The dividend is subject to approval by shareholders at the 30th Annual General Meeting (AGM) scheduled for August 11, 2026. - Payment will be made within 30 days of the AGM date.

Financials Positive

2026-07-17 18:26

- Board recommended a final dividend of ₹1/- per equity share (10%) for FY 2025-26. - Record date for dividend payment is July 24, 2026. - The dividend is subject to approval at the AGM on August 11, 2026, and will be paid within 30 days thereafter.

Governance Neutral

2026-07-17 18:23

- Fortis Healthcare informed shareholders about the weblink to its FY2025-26 Annual Report and AGM Notice. - The 30th Annual General Meeting (AGM) is scheduled for Tuesday, August 11, 2026, at 12:00 Noon (IST) via Video Conference. - Documents are accessible on the company's website.

Governance Positive

2026-07-17 18:13

- The 30th Annual General Meeting (AGM) is scheduled for August 11, 2026, at 12:00 IST. - Record date for dividend is July 24, 2026. - E-voting will be available from August 06 to August 10, 2026. - The Annual Report includes positive Business Responsibility and Sustainability Report (BRSR) highlights for FY25-26.

Governance Neutral

2026-07-17 17:17

- Fortis Healthcare Limited will hold its 30th Annual General Meeting (AGM) on Tuesday, August 11, 2026, at 12:00 hours (IST) via Video Conferencing (VC)/Other Audio-Visual Means (OAVM). - Shareholders will consider and adopt the Audited Financial Statements for the financial year ended March 31, 2026. - A final dividend of ₹1/- per equity share for FY 2025-26 is proposed. - Re-appointment of Mr. Ashok Pandit and Dr. Prem Kumar Nair as Directors, and Dr. Ashutosh Raghuvanshi as MD & CEO, are on the agenda. - Remote e-voting will be available from August 06, 2026, to August 10, 2026. - The record date for dividend payment is July 24, 2026, and the cut-off date for e-voting eligibility is August 04, 2026.

Governance Positive

2026-07-08 14:48

- Board of Directors approved the re-appointment of Dr. Ashutosh Raghuvanshi as Managing Director and CEO for two years, effective March 19, 2027, subject to shareholder approval.

Governance Positive

2026-07-08 14:39

- The Board of Directors, in a meeting on July 8, 2026, recommended the re-appointment of Dr. Ashutosh Raghuvanshi as Managing Director and CEO for a further period of two years, effective March 19, 2027. - The re-appointment is subject to shareholder approval.

Business Update Positive

2026-07-03 17:36

- Fortis Healthcare has signed an Operations and Management (O&M) agreement with Dion Group. - The agreement is for a 300-bed greenfield multi-specialty hospital to be developed at Dion Riverside Township, Trishulia in Cuttack, Odisha. - The partnership aims to strengthen healthcare infrastructure and improve access to advanced medical care across Eastern India.

Routine Neutral

2026-06-24 16:42

- Trading Window for dealing in shares of Fortis Healthcare Limited will be closed from July 01, 2026. - The closure will last until 48 hours after the declaration of unaudited financial results for the quarter ending June 30, 2026. - This is in accordance with the Policy/Code of Conduct for Prevention of Insider Trading.

Business Update Positive

2026-06-17 12:19

- Fortis Healthcare's subsidiary, Fortis Hospitals Limited, had its Income Tax demand for AY 2024-25 reduced following a successful rectification application. - The tax demand decreased from ₹117.04 Crores to ₹61.48 Crores.

Business Update Positive

2026-05-29 16:20

Fortis Healthcare reported a steady performance in FY26 with improved consolidated operating EBITDA margins at 22.8% (up from 20.4% in FY25) and hospital business operating EBITDA margins at 22.2% (up from 20.5% in FY25). A dividend of INR1 per share was recommended. The company added approximately 800 beds in FY26 through brownfield expansion and acquisitions, with a Capex of INR700 crores. Management guided for 15%+ revenue growth and 150 basis points EBITDA margin improvement for the hospital business in FY27, targeting 25% EBITDA margin by FY28 with 1.5-2% YoY improvement. Diagnostic business (Agilus) is expected to achieve 23-24% EBITDA margins and double-digit revenue growth in FY27, driven by 5% volume growth. The company plans to add ~1,800 beds over the next four years, including ~400 beds in FY27, with annual Capex of ~INR900 crores. IHH plans to increase its stake to 50% with INR10,000 crores equity infusion for growth. Occupancy dip in some hospitals attributed to international business and onco drug capping is being addressed by seeking alternate business opportunities.

Business Update Neutral

2026-05-25 20:46

Fortis Healthcare Limited has announced the availability of the audio recording of the investors/analysts meet held on May 25, 2026. The meeting discussed the company's Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026, and the recording is accessible on the company's website.

Financials Negative

2026-05-22 21:09

CRITICAL RED FLAG DETECTED

Fortis Healthcare Limited reported Q4 FY26 consolidated Revenue of ₹2,364.67 Cr vs ₹2,007.20 Cr (▲17.81% YoY), EBITDA of ₹542.94 Cr vs ₹459.91 Cr (▲18.05% YoY), and PAT of ₹271.19 Cr vs ₹188.02 Cr (▲44.23% YoY). EBITDA Margin was 22.96% vs 22.91% (▲5bps). The Board recommended a final dividend of ₹1/- per equity share for FY 2025-26. The auditor's report highlights an ongoing SFIO investigation into alleged improper transactions and non-compliances, and a Supreme Court order for considering a forensic audit related to past transactions concerning RHT Health Trust.

Routine Neutral

2026-05-22 20:56

New Filing detected. See link for details.

Financials Neutral

2026-05-22 20:52

CRITICAL RED FLAG DETECTED

Consolidated Revenue for Q4 FY26 was ₹2,364.67 Cr (up 17.8% YoY), EBITDA was ₹538.55 Cr (up 22.4% YoY), and PAT was ₹271.19 Cr (up 44.2% YoY). EBITDA Margin expanded by 85 bps to 22.77%. The Board recommended a final dividend of ₹1/- per equity share for FY26. Auditors highlighted an ongoing SFIO investigation and a Supreme Court order regarding alleged improper transactions and non-compliances, though their opinion on the financial results was unmodified.

Financials Positive

2026-05-22 20:48

CRITICAL RED FLAG DETECTED

The company reported strong consolidated financial results for the quarter ended March 31, 2026. Consolidated Revenue stood at ₹2,364.67 Cr versus ₹2,007.20 Cr (▲17.8% YoY), EBITDA at ₹530.45 Cr versus ₹406.34 Cr (▲30.6% YoY), and PAT at ₹271.19 Cr versus ₹188.02 Cr (▲44.2% YoY). EBITDA Margin expanded from 20.24% to 22.43% (▲219bps). The Board also recommended a final dividend of ₹1/- per equity share for the financial year 2025-26. Auditors issued an unmodified opinion on the financial results.

Financials Positive

2026-05-22 20:32

Consolidated Revenue ₹2,365Cr vs ₹2,007Cr (▲17.8% YoY), EBITDA ₹531Cr vs ₹435Cr (▲22.2% YoY), PAT ₹271Cr vs ₹188Cr (▲44.2% YoY). EBITDA Margin 22.5% vs 21.7% (▲80bps). The Board also recommended a dividend of INR 1 per share (10% of Face Value).

Financials Negative

2026-05-22 20:24

CRITICAL RED FLAG DETECTED

Consolidated Revenue ₹2364.67 Cr vs ₹2007.20 Cr (▲17.81% YoY), EBITDA ₹526.06 Cr vs ₹386.54 Cr (▲36.08% YoY), PAT ₹271.19 Cr vs ₹188.02 Cr (▲44.23% YoY). EBITDA Margin 22.25% vs 19.26% (▲299bps). The company also recommended a final dividend of ₹1 per equity share. The audit report highlights an ongoing Serious Fraud Investigation Office (SFIO) investigation regarding alleged improper transactions and non-compliances.

Financials Positive

2026-05-22 20:11

CRITICAL RED FLAG DETECTED

Consolidated Revenue ₹2,364.67 Cr vs ₹2,007.20 Cr (▲17.8% YoY), EBITDA ₹526.06 Cr vs ₹386.54 Cr (▲36.1% YoY), PAT ₹271.19 Cr vs ₹188.02 Cr (▲44.2% YoY). EBITDA Margin 22.25% vs 19.26% (▲299bps). The company also recommended a final dividend of ₹1/- per equity share for FY 2025-26. The auditor's report noted ongoing SFIO investigations and a Supreme Court order for a potential forensic audit regarding past transactions, though their opinion on the financial results was unmodified.

Financials Negative

2026-05-22 20:07

CRITICAL RED FLAG DETECTED

Consolidated Revenue ₹2,364.67 Cr vs ₹2,007.20 Cr (▲17.81% YoY), EBITDA ₹536.72 Cr vs ₹455.27 Cr (▲17.89% YoY), PAT ₹271.19 Cr vs ₹188.02 Cr (▲44.23% YoY). EBITDA Margin 22.71% vs 22.68% (▲3bps).

Financials Neutral

2026-05-15 17:19

Fortis Healthcare Limited announced an investors/analysts conference call to discuss the Company's Q4FY26 and Full Year FY26 audited financial results. The call is scheduled for Monday, May 25, 2026, at 11:00 am (IST).

Business Update Neutral

2026-04-29 13:49

Fortis Healthcare, referencing an announcement by IHH Healthcare Berhad, disclosed an update on the material litigation between its promoter, Northern TK Venture Pte Ltd, and Daiichi Sankyo Company Limited. The Tokyo District Court has concluded the preparatory and oral proceedings for NTK's claim, with the judgment scheduled for September 10, 2026.

Business Update Positive

2026-04-23 14:09

Fortis Healthcare Limited's Nomination & Remuneration Committee approved the grant of up to 1,32,05,200 employee stock options under its ESOP Scheme 2026. The options have an exercise price of INR 923.10 per option and are granted to eligible employees.

Business Update Neutral

2026-04-22 17:09

Fortis Healthcare will hold in-person investor/analyst meetings (Non Deal Roadshow) on April 27th and 28th, 2026, in Mumbai, organized by JM Financial. The meetings will cover general business updates and industry discussions.

Business Update Neutral

2026-04-22 17:07

Fortis Healthcare will hold an investor/analyst Non Deal Roadshow in Mumbai on April 27-28, 2026, organized by JM Financial, to discuss general business updates and industry trends. No UPSI will be shared.

Routine Positive

2026-04-10 12:49

Fortis Healthcare filed its FY26 disclosure for corporate bonds/debentures. The credit rating for these instruments was upgraded by CRISIL from AA to AA+. All interest payments due on December 22, 2025, were made on time, with no reported defaults.

Routine Neutral

2026-04-08 18:33

New Filing detected. See link for details.

Routine Neutral

2026-04-08 16:26

Fortis Healthcare Limited submitted certificates under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026. KFin Technologies Limited, the Registrar and Transfer Agent, certified the details of securities dematerialized/rematerialized during the period.

Routine Neutral

2026-04-01 11:04

New Filing detected. See link for details.

Business Update Negative

2026-03-28 14:12

CRITICAL RED FLAG DETECTED

Fortis Healthcare's subsidiary, Fortis Hospitals Limited, received an Income Tax Order dated March 27, 2026, for AY 2024-25, raising a demand of INR 117.04 Crores. The company is evaluating all options including filing an appeal against the order.

Routine Neutral

2026-03-25 15:59

Fortis Healthcare Limited announced the closure of its trading window for dealing in company shares from April 1, 2026, until 48 hours after the declaration of Audited Financial Results for the quarter and financial year ended March 31, 2026, to prevent insider trading.

Governance Positive

2026-03-18 22:29

Fortis Healthcare Limited shareholders approved the Fortis Healthcare Limited Employees Stock Option Scheme 2026 and the grant of stock options to eligible employees of its subsidiary and associate companies with requisite majority via postal ballot dated March 18, 2026.

Governance Positive

2026-03-18 22:24

Fortis Healthcare Limited announced the results of its postal ballot on March 18, 2026. Shareholders approved with requisite majority the Fortis Healthcare Limited Employees Stock Option Scheme 2026 and the grant of employee stock options to eligible employees of its subsidiary and associate companies under the scheme.

Business Update Positive

2026-03-02 02:00

Fortis Healthcare Limited filed the certified NCLT order for a composite scheme of merger by absorption of its wholly-owned subsidiaries (FESL, FCCL, FHMEL, B&B) with Fortis Hospitals Limited. The scheme became effective on March 1, 2026.

Financials Positive

2026-02-20 13:14

Consolidated Revenue ₹2,265Cr vs ₹1,928Cr (▲17.5% YoY), EBITDA ₹505Cr vs ₹375Cr (▲34.8% YoY), PAT ₹197Cr vs ₹250Cr (▼21.2% YoY). EBITDA Margin 22.3% vs 19.4% (▲290bps). PAT decline due to one-off exceptional loss of ₹46Cr.

Business Update Negative

2026-02-19 16:50

Fortis Healthcare announced an update on material litigation where its promoter, Northern TK Venture, filed an amended petition against Daiichi Sankyo for tortious losses of over INR 109 billion and defamation, also seeking injunctions to prevent obstruction of Fortis and Malar share acquisitions.

Business Update Neutral

2026-02-16 22:48

Fortis Healthcare announced the audio recording of the investor/analyst meet held on February 16, 2026, is available. The meet discussed unaudited Q3 FY26 standalone and consolidated financial results for the quarter ended December 31, 2025.

Governance Positive

2026-02-16 22:21

Fortis Healthcare Limited is seeking shareholder approval via postal ballot for its ESOP 2026, including granting up to 1,50,99,163 options to employees of the company, subsidiaries, and associates. The e-voting period is from Feb 17 to March 18, 2026.

Governance Positive

2026-02-16 22:18

Fortis Healthcare will conduct a postal ballot for shareholder approval of the Fortis Healthcare Limited Employees Stock Option Scheme 2026, including granting options to employees of the company, subsidiaries, and associates. E-voting runs from February 17 to March 18, 2026.

Financials Negative

2026-02-13 20:02

CRITICAL RED FLAG DETECTED

Board approved Q3 FY26 Un-Audited Consolidated and Standalone Financial Results, Fortis Healthcare Limited ESOP 2026, and revised Related Party Transaction Policy. The audit report notes ongoing SFIO/EOW investigations and a Supreme Court directive for forensic audits.

Financials Positive

2026-02-13 19:18

Consolidated Revenue ₹2,265Cr vs ₹1,928Cr (▲17.5% YoY), Operating EBITDA ₹505Cr vs ₹375Cr (▲34.8% YoY), PAT ₹197Cr vs ₹254Cr (▼22.4% YoY, impacted by exceptional items). EBITDA Margin 22.3% vs 19.4% (▲290bps).

Financials Positive

2026-02-13 19:15

Consolidated Revenue ₹2,265Cr vs ₹1,928Cr (▲17.5% YoY), Operating EBITDA ₹505Cr vs ₹375Cr (▲34.8% YoY), PAT (excl. exceptional) ₹243Cr vs ₹230.2Cr (▲5.6% YoY). EBITDA Margin 22.3% vs 19.4% (▲290bps).

Financials Negative

2026-02-13 18:53

CRITICAL RED FLAG DETECTED

Fortis Healthcare announced its Q3 FY26 unaudited standalone and consolidated financial results and an Employee Stock Option Scheme. The auditor's report highlighted ongoing SFIO and EOW investigations, alleged improper transactions, and a Supreme Court order for a potential forensic audit into past transactions.

Financials Negative

2026-02-13 18:51

CRITICAL RED FLAG DETECTED

Board approved Q3 FY26 standalone results, ESOP 2026, and revised RPT policy. The filing notes ongoing SFIO investigation and Supreme Court's direction for a potential forensic audit regarding past transactions and the IHH acquisition, raising significant regulatory and legal concerns.

Business Update Neutral

2026-02-06 13:54

Fortis Healthcare Limited announced an Investors/Analysts' conference call on Monday, February 16, 2026, at 11:00 am IST to discuss the company's unaudited financial results for the quarter ended December 31, 2025. Dial-in and replay details are provided in the filing.

FORTIS

Fortis Healthcare Limited

Price Chart

Filing History

Unlock Full History